Skip to content
DataLookout
Menu

LONG-LIFENCT07719088

Psilocybin Effects on Healthy Aging Biomarkers and Purpose in Life

StatusRecruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 4 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened
    • Start date changed from estimate of Dec 2026 to Nov 16, 2026
    • Site details revised
  2. Notable Primary endpoints: details revised at 1 of 2 entries
    • Eligibility criteria expanded, about 5 words
    • Secondary endpoints: details revised at 6 of 8 entries
  3. Minor Secondary endpoints: details revised at 5 of 8 entriesv2
  4. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Change in Epigenetic/Biological Clock Profiling from Baseline to Week 4 and Week 16
Timeframe: Change from Baseline to Week 4 and Week 16
Change in Purpose in Life (PIL) from Baseline to Week 4 and Week 16
Timeframe: Change from Baseline to Week 4 and Week 16

Secondary (8)

Change in Epigenetic/Biological Clock Profiling from Baseline to Week 52
Change in Telomere Length from Baseline to Week 52
Change in Purpose in Life (PIL) from Baseline to Week 52
Change in Satisfaction with Life from Baseline to Week 4 and Week 16
Change in Wellbeing from Baseline to Week 4 and Week 16
Show 3 moreShow less
Change in Optimism from Baseline to Week 4 and Week 16
Change in Perceived Control/Mastery from Baseline to Week 4 and Week 16
Change in Loneliness from Baseline to Week 4 and Week 16

Arms and interventions

One 25mg Dose of PsilocybinExperimental

Participants in this arm will receive one 25mg dose of psilocybin paired with therapeutic support.

Two 25mg Doses of PsilocybinExperimental

Participants in this arm will receive two 25mg doses of psilocybin approximately 4 weeks apart paired with therapeutic support.

Three 25mg Doses of PsilocybinExperimental

Participants in this arm will receive three 25mg doses of psilocybin approximately 4 weeks apart paired with therapeutic support.

Wait-list ComparatorNo intervention

Participants in this arm will not receive psilocybin as part of the main study but will be given the opportunity to receive a single 25mg dose of psilocybin with therapeutic support after their study participation is complete.

Drugs: Psilocybin (Usona Institute)

Sites

1 site in 1 country

  • Vail Health Behavioral HealthEdwards, Colorado, United States